Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
10
×
biotech
10
×
boston blog main
10
×
life sciences
national blog main
boston top stories
national top stories
new york blog main
new york top stories
clinical trials
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
deals
eli lilly
fda
alirocumab
alnylam pharmaceuticals
cancer
diagnostics
evolocumab
inclisiran
merck
What
drug
10
×
new
fda
medicines
approval
bio
cholesterol
migraine
roundup
won
acquisitions
biggest
brings
ceo
class
company
decades
drugs
lowering
medco
patients
wave
acquire
acute
addresses
advantages
agreed
albert
alnylam
amgen
arguments
bar
based
big
billion
bourla
build
buy
cancer
candidates
Language
unset
unknown
Current search:
drug
×
biotech
×
" boston blog main "
×
amgen
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines